Diana Yu, MD
Pulmonary Disease · San Francisco, CANPI 1639494297
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (33.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Intuitive Surgical at 51.5% of the total. Reporting peaked in 2023 at $7,349 and has fallen 96.5% since, to $258 in 2025.
Across 62 payments — averaging $253.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Abbott$4K
- Auris Health, Inc.$1K
- Covidien LP$894
- Johnson & Johnson$444
- Pulmonx Corporation$293
- plus $505 from 6 others
What the payments were for
- Consulting fees$5,20033%
- Speaking & faculty fees$2,00013%
- Travel & lodging$2,33915%
- Food & beverage$3,20320%
- Education$3,00019%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 31 | $8,108 |
| Abbott | 7 | $4,071 |
| Auris Health, Inc. | 2 | $1,429 |
| Covidien LP | 4 | $894 |
| Johnson & Johnson | 4 | $444 |
| Pulmonx Corporation | 5 | $293 |
| Boston Scientific | 1 | $123 |
| Olympus America Inc. | 3 | $123 |
| Medtronic | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 1 | $81 |
| Coaptech, Inc. | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre Pro$3,800
- ION$3,000
- Da Vinci Surgical System$2,271
- DA VINCI SP$2,000
- MONARCH$1,400
- superDimension$846
- Monarch Platform$413
- ACQUIRE$123
- Pulmonx Endobronchial Valve EBV$115
- ILLUMISITE$100
How this compares
$15,742 in reported general payments places this provider in the 85th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,128 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in San Francisco
- Nicholas KolaitisSan Francisco$122K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.